{
    "clinical_study": {
        "@rank": "164958", 
        "arm_group": {
            "arm_group_label": "rVIII-SingleChain", 
            "arm_group_type": "Experimental", 
            "description": "Subjects will receive rVIII-SingleChain as an intravenous (IV) infusion based on the investigator's judgment and the subject's tolerability for both on-demand and prophylaxis treatment with a recommended dose between 15 to 50 IU/kg as prescribed.  All subjects will be treated for a minimum of 50 EDs. For the PK evaluation, the subjects will receive a single IV dose of 50 IU/kg of rVIII-SingleChain on Day 1 at the start of the PK evaluation period."
        }, 
        "brief_summary": {
            "textblock": "This is an international, multicenter, open-label study to assess the efficacy, safety, and\n      pharmacokinetic (PK) profile of rVIII-SingleChain in pediatric patients with severe\n      hemophilia A. A minimum of 25 previously treated subjects \u2265 6 to < 12 years of age and at\n      least 25 subjects < 6 years of age who have undergone > 50 exposure days (EDs) with a\n      previous Factor VIII (FVIII) product are planned to be enrolled. Subjects will be assigned\n      to either an on-demand or prophylaxis treatment regimen for the treatment of bleeding\n      episodes and will receive rVIII-SingleChain at a dose to be determined by the investigator.\n      Hemostatic efficacy will be assessed by the subject/caregiver and the investigator who will\n      assess overall efficacy by a 4-point scale."
        }, 
        "brief_title": "Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Congenital Hemophilia A", 
        "condition_browse": {
            "mesh_term": "Hemophilia A"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of severe hemophilia A defined as < 1% Factor VIII (FVIII) concentration\n             (FVIII:C) documented in medical records,\n\n          -  Males < 12 years of age,\n\n          -  Subjects who have received > 50 EDs with a FVIII product,\n\n          -  Prior PK data (at least incremental recovery and half-life) from previous FVIII\n             exposure for subjects participating in the PK part\n\n          -  Investigator believes that the subject is willing and able to adhere to all protocol\n             requirements.  Investigator believes that the subject's parent(s) or legally\n             acceptable representative(s) is / are willing and able to adhere to all protocol\n             requirements.\n\n        Exclusion Criteria:\n\n          -  Any history of or current FVIII inhibitors\n\n          -  Use of an Investigational Medical Product (IMP) within 30 days prior to the first\n             rVIII-SingleChain administration,\n\n          -  Administration of any cryoprecipitate, whole blood or plasma within 30 days prior to\n             administration of rVIII-SingleChain,\n\n          -  Known hypersensitivity (allergic reaction or anaphylaxis) to any FVIII product or\n             hamster protein,\n\n          -  Subject currently receiving IV immunomodulating agents such as immunoglobulin or\n             chronic systemic corticosteroid treatment,\n\n          -  Subject with serum aspartate aminotransferase (AST) or serum alanine aminotransferase\n             (ALT) values >5 times (x) the upper limit of normal (ULN) at Screening,\n\n          -  Subjects with serum creatinine values >2 x ULN at Screening,\n\n          -  Evidence of thrombosis, including deep vein thrombosis, stroke, pulmonary embolism,\n             myocardial infarction and arterial embolus within 3 months before Day 1,\n\n          -  Experienced life-threatening bleeding episode or had major surgery or an orthopedic\n             surgical procedure during the 3 months before rVIII-SingleChain administration."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "11 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02093897", 
            "org_study_id": "CSL627_3002", 
            "secondary_id": "2012-001336-65"
        }, 
        "intervention": {
            "arm_group_label": "rVIII-SingleChain", 
            "intervention_name": "rVIII-SingleChain", 
            "intervention_type": "Biological", 
            "other_name": [
                "Recombinant Factor VIII single chain", 
                "CSL627"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Factor VIII"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 1, 2014", 
        "location": {
            "contact": {
                "last_name": "Use Central Contact"
            }, 
            "facility": {
                "address": {
                    "city": "Kuala Lumpur", 
                    "country": "Malaysia", 
                    "zip": "50400"
                }, 
                "name": "Study Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Malaysia"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase III Open-label Pharmacokinetic, Efficacy and Safety Study of rVIII-SingleChain in a Pediatric Population With Severe Hemophilia A", 
        "overall_contact": {
            "email": "clinicaltrials@cslbehring.com", 
            "last_name": "Clinical Trials Registration Coordinator"
        }, 
        "overall_official": {
            "affiliation": "CSL Behring", 
            "last_name": "Program Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Hungary: National Institute of Pharmacy", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Rate of treatment success where treatment success of a bleeding episode is defined as a rating of \"excellent\" or \"good\" based on the investigator's overall clinical assessment of hemostatic efficacy (using a 4-point scale of excellent, good, moderate or poor/no response).", 
            "measure": "Treatment success", 
            "safety_issue": "No", 
            "time_frame": "Up to two years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02093897"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The annualized bleeding rate is defined as the number of bleeds from all causes (traumatic and non-traumatic) divided by the treatment period in years.", 
                "measure": "Annualized bleeding rate", 
                "safety_issue": "No", 
                "time_frame": "Up to two years"
            }, 
            {
                "measure": "Proportion of bleeding episodes requiring 1, 2, 3, or more than 3 infusions of rVIII-SingleChain to achieve hemostasis.", 
                "safety_issue": "No", 
                "time_frame": "Up to two years"
            }, 
            {
                "description": "rVIII-SingleChain consumed as measured by:\nnumber of infusions per month and per year per subject\nIU/kg per event", 
                "measure": "Consumption of rVIII-SingleChain", 
                "safety_issue": "No", 
                "time_frame": "Up to two years"
            }, 
            {
                "description": "Incremental recovery expressed as (IU/mL)/(IU/kg)", 
                "measure": "Incremental recovery", 
                "safety_issue": "No", 
                "time_frame": "0 to 2 days after infusion"
            }, 
            {
                "measure": "Half-life (t1/2) of rVIII-SingleChain", 
                "safety_issue": "No", 
                "time_frame": "0 to 2 days after infusion"
            }, 
            {
                "description": "AUC to the last sample with quantifiable drug concentration (AUC0-t).", 
                "measure": "Area under the concentration curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "0 to 2 days after infusion"
            }, 
            {
                "measure": "Clearance (Cl) of rVIII-SingleChain", 
                "safety_issue": "No", 
                "time_frame": "0 to 2 days after infusion"
            }, 
            {
                "description": "The number of subjects who develop inhibitors to rVIII-SingleChain, defined as a rVIII-SingleChain antibody titer of at least 0.6 Bethesda Units (BU) per mL after receiving study drug.", 
                "measure": "The number of subjects with inhibitor formation to rVIII-SingleChain", 
                "safety_issue": "Yes", 
                "time_frame": "Up to two years"
            }
        ], 
        "source": "CSL Behring", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CSL Behring", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}